Free tool
FAERS Monitor: Trikafta (Copackaged)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212273 or its brand name (Trikafta (Copackaged), Elexacaftor, Ivacaftor, Tezacaftor, Ivacaftor). Reports on generic versions are filed under their own applications.
Reports
12,580
Serious
5,317
42% of reports
Hospitalization
3,485
Death reported
247
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infective pulmonary exacerbation of cystic fibrosis823
- headache776
- anxiety635
- cough602
- rash573
- fatigue546
- productive cough545
- weight increased521
- cystic fibrosis513
- abdominal pain upper480
- depression461
- hospitalisation443
- pneumonia399
- diarrhoea389
- mental disorder357
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 500 |
| 2020 | 5,170 |
| 2021 | 1,161 |
| 2022 | 1,050 |
| 2023 | 1,297 |
| 2024 | 1,438 |
| 2025 | 1,259 |
| 2026 | 704 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,579 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 823 | 297.6 | 276.9 | 206,357 |
| cystic fibrosisSignal | 513 | 170.6 | 156.1 | 78,365 |
| productive coughSignal | 545 | 19.3 | 17.8 | 9,351 |
| mental disorderSignal | 357 | 13.8 | 12.5 | 4,207 |
| hospitalisationSignal | 443 | 4.8 | 4.4 | 1,348 |
| abdominal pain upperSignal | 480 | 3.9 | 3.6 | 1,042 |
| weight increasedSignal | 521 | 3.9 | 3.6 | 1,128 |
| anxietySignal | 635 | 3.7 | 3.5 | 1,285 |
| coughSignal | 602 | 3.6 | 3.3 | 1,138 |
| depressionSignal | 461 | 3.4 | 3.1 | 782 |
| rashSignal | 573 | 2.2 | 2.0 | 381 |
| headacheSignal | 776 | 2.1 | 1.9 | 441 |
| pneumoniaSignal | 399 | 2.1 | 1.9 | 220 |
| fatigue | 546 | 1.2 | 1.1 | 14 |
| diarrhoea | 389 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.